I wouldn't be too sure of that. If the topline UP matches the cohorts 1 and 2 and OM has another 5-6 treated with the same stats as the interim it could move. The outcomes in those trials are quite a bit more decisive than what we was in P 2a. They would also signal that B is ripe for partnership.
I think we'll need P 2B interim results before a decision on any deal will be made. But wouldn't it be nice if we were less than a month out from a partnership? One can hope. Hope hurts until it doesn't.
(2)
(1)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.